Publication:
The turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?

Thumbnail Image

Organizational Units

Authors

Şen, Sedat
Tuncer, Aslı
Özakbaş, Serkan
Uzunköprü, Cihat
Baba, Cavid
Demir, Serkan
Beckmann, Yeşim
Gümüş, Haluk
Arslan, Gökhan
Kılıç, Ahmet Kasım

Advisor

Language

Publisher:

Elsevier

Journal Title

Journal ISSN

Volume Title

Abstract

Background: COVID-19 is a multisystemic infection with variables consequences depending on individual and comorbid conditions. The course and outcomes of COVID-19 during neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disorders (MOGAD) are not clearly known.Objective/methods: The aim of this study was to examine the features and outcomes of COVID-19 infection in NMOSD and MOGAD patients. The patients' demographic and clinical factors, disease modifying treatment (DMT) used and disease information of COVID-19 infection were recorded. Conditions leading to hospitalization and severe exposure to COVID-19 infection were also analyzed.Results: The study included 63 patients from 25 centers. Thirty-two patients (50.8%) belong to AQP-4 seropositive group, 13 (20.6%) and 18 (28.6%) were in MOG-positive and double-seronegative groups, respectively. Risk factors for severe COVID-19 infection and hospitalization were advanced age, high disability level and the presence of comorbid disease. Disease severity was found to be high in double-seronegative NMOSD and low in MOGAD patients. No statistically significant effect of DMTs on disease severity and hospitalization was found.Conclusion: In NMOSD and MOGAD patients, advanced age, high disability and presence of comorbid disease pose risks for severe COVID-19 infection. There was no direct significant effect of DMTs for COVID-19 infection.

Description

Source:

Keywords:

Keywords

Neuromyelitis optica spectrum disorders, Myelin oligodendrocyte glycoprotein antibody-associated disorders, Disease modifying treatment, Coronavirus, Sars-cov-2, Science & technology, Life sciences & biomedicine, Clinical neurology, Neurosciences & neurology

Citation

Endorsement

Review

Supplemented By

Referenced By

2

Views

8

Downloads

View PlumX Details